PARP inhibitors may be effective against non-small-cell lung cancer: Study Yesterday 03:49 下午 ET • BMRN A new study published in Oncogene reportedly suggests PARP inhibitors such as BioMarin's (BMRN +0.7%) BMN 673 and Tesaro's (TSRO +0.1%) Niraparib may be effective in treating non-small-cell lung cancer. BMRN recently gave a program update on BMN 673, noting that the RECIST rate in breast cancer patients had risen to 50%. The company also said "data in ovarian cancer, Ewing's sarcoma and small cell lung cancer" should come "later this year." TSRO launched a Phase 3 trial of Niraparib for patients with ovarian cancer late last month. Other PARP inhibitors: AstraZeneca's (AZN +0.5%) olaparib.